Glenmark Pharmaceuticals Inc., USA (Glenmark) announces
the launch of Lacosamide Oral Solution, 10 mg/mL. Glenmark's Lacosamide Oral Solution, 10 mg/mL is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat2 Oral Solution, 10
mg/mL of UCB, Inc.
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
